Dual renin-angiotensin blockage and total embryo cryopreservation is not a risk-free strategy in patients at high risk for ovarian hyperstimulation syndrome

Fertility and Sterility

Volumn 90, Issue 3, 2008, Pages 531-536

  Ata, Baris ^a,b   Yakin, Kayhan ^a   Alatas, Cengiz ^a   Urman, Bulent ^a  

^a AMERICAN HOSPITAL   (Turkey)

^b Soranus IVF Clinic   (Turkey)

Author keywords

ace inhibitor; angiotensin receptor blocker; Ovarian hyperstimulation syndrome; renin angiotensin system

Indexed keywords

CANDESARTAN HEXETIL; ENALAPRIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; FEMALE; FERTILIZATION; HOSPITALIZATION; HUMAN; OOCYTE; OVARY HYPERSTIMULATION; PREGNANCY RATE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; COMBINED MODALITY THERAPY; CRYOPRESERVATION; EMBRYO TRANSFER; ENALAPRIL; FEMALE; FERTILIZATION IN VITRO; HUMANS; MALE; OVARIAN HYPERSTIMULATION SYNDROME; RECEPTORS, ANGIOTENSIN; RISK ASSESSMENT; RISK FACTORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 51449091658     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.07.1309     Document Type: Article

References (39)

1. Rizk B. Pathophysiology of ovarian hyperstimulation syndrome. In: Rizk B. (Ed). Ovarian hyperstimulation syndrome (2006), Cambridge University Press, New York 43
2. Rizk B., and Aboulghar M. Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: Brindsen P. (Ed). A textbook of in-vitro fertilization and assisted reproduction (1999), Parthenon, Carnforth
3. Rizk B., Aboulghar M., Smitz J., and Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 3 (1997) 255-266
4. Delbaere A., Bergmann P.J., Gervy-Decoster C., Camus M., de Maertelaer V., and Englert Y. Prorenin and active renin concentrations in plasma and ascites during severe ovarian hyperstimulation syndrome. Hum Reprod 12 (1997) 236-240
5. Morris R.S., Wong I.L., Kirkman E., Gentschein E., and Paulson R.J. Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod 10 (1995) 1355-1358
6. Rizk B., Aboulghar M., Mansour R., Serour G., and Amin Y. Severe ovarian hyperstimulation syndrome: analytical study of twenty-one cases. Hum Reprod 8 (1991) 368-369
7. Ohba T., Ujioka T., Ishikawa K., Tanaka N., and Okamura H. Ovarian hyperstimulation syndrome-model rats: the manifestation and clinical implication. Mol Cell Endocrinol 202 (2003) 47-52
8. Gomez R., Gonzalez-Izquierdo M., Zimmermann R.C., Novella-Maestre E., Alonso-Muriel I., Sanchez-Criado J., et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 147 (2006) 5400-5411
9. Palumbo A., Carcangiu M.L., Roa L., Pepperell J., Pourmotabbed G., and Naftolin F. The ovarian renin-angiotensin system in polycystic ovarian syndrome. Ann N Y Acad Sci 687 (1993) 39-45
10. Rizk B., and Abdalla H. Ovulatory dysfunction and its management. In: Rizk B., and Abdullah M. (Eds). Infertility and assisted reproductive technology (2006), Health Press, Oxford 87-89
11. Ong A.C., Eisen V., Rennie D.P., Homburg R., Lachelin G.C., Jacobs H.S., et al. The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin. Clin Endocrinol (Oxf) 34 (1991) 43-49
12. Blankestijn P.J., Derkx F.H., Van Geelen J.A., De Jong F.H., and Schalekamp M.A. Increase in plasma prorenin during the menstrual cycle of a bilaterally nephrectomized woman. Br J Obstet Gynaecol 97 (1990) 1038-1042
13. Itskovitz J., and Sealey J.E. Ovarian prorenin-renin-angiotensin system. Obstet Gynecol Surv 42 (1987) 545-551
14. Culler M.D., Tarlatzis B.C., Lightman A., Fernandez L.A., Decherney A.H., Negro-Vilar A., et al. Angiotensin II-like immunoreactivity in human ovarian follicular fluid. J Clin Endocrinol Metab 62 (1986) 613-615
15. Fernandez L.A., Tarlatzis B.C., Rzasa P.J., Caride V.J., Laufer N., Negro-Vilar A.F., et al. Renin-like activity in ovarian follicular fluid. Fertil Steril 44 (1985) 219-223
16. Navot D., Margalioth E.J., Laufer N., Birkenfeld A., Relou A., Rosler A., et al. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 48 (1987) 57-61
17. Ando H., Furugori K., Shibata D., Harata T., Murata Y., and Mizutani S. Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series. Hum Reprod 18 (2003) 1219-1222
18. Hardarson T., Hanson C., Sjogren A., and Lundin K. Human embryos with unevenly sized blastomeres have lower pregnancy and implantation rates: indications for aneuploidy and multinucleation. Hum Reprod 16 (2001) 313-318
19. Balaban B., Yakin K., Isiklar A., and Urman B. Utilization of high-security straws for embryo freezing in an in vitro fertilization program: a prospective, randomized study. Fertil Steril 87 (2007) 691-696
20. Ata B., Isiklar A., Balaban B., and Urman B. Prospective randomized comparison of Wallace and Labotect embryo transfer catheters. Reprod Biomed Online 14 (2007) 471-476
21. Rizk B. Prevention of ovarian hyperstimulation syndrome. In: Rizk B. (Ed). Ovarian hyperstimulation syndrome (2006), Cambridge University Press, New York 130
22. Delvigne A., and Rozenberg S. Preventive attitude of physicians to avoid OHSS in IVF patients. Hum Reprod 16 (2001) 2491-2495
23. Wada I., Matson P.L., Troup S.A., Morroll D.R., Hunt L., and Lieberman B.A. Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition?. Br J Obstet Gynaecol 100 (1993) 265-269
24. Pattinson H.A., Hignett M., Dunphy B.C., and Fleetham J.A. Outcome of thaw embryo transfer after cryopreservation of all embryos in patients at risk of ovarian hyperstimulation syndrome. Fertil Steril 62 (1994) 1192-1196
25. Queenan Jr. J.T., Veeck L.L., Toner J.P., Oehninger S., and Muasher S.J. Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. Hum Reprod 12 (1997) 1573-1576
26. Ferraretti A.P., Gianaroli L., Magli C., Fortini D., Selman H.A., and Feliciani E. Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Hum Reprod 14 (1999) 1457-1460
27. Shaker A.G., Zosmer A., Dean N., Bekir J.S., Jacobs H.S., and Tan S.L. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Fertil Steril 65 (1996) 992-996
28. Chang F., Chan C., Yin Y., and Wu G. Predicted value of renin activity in a woman who had severe ovarian hyperstimulation with internal jugular vein thrombosis. Fertil Steril 82 (2004) 937-939
29. Yoshimura Y., Koyama N., Karube M., Oda T., Akiba M., Yoshinaga A., et al. Gonadotropin stimulates ovarian renin-angiotensin system in the rabbit. J Clin Invest 93 (1994) 180-187
30. Le Noble F.A., Hekking J.W., Van Straaten H.W., Slaaf D.W., and Struyker Boudier H.A. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur J Pharmacol 195 (1991) 305-306
31. Robertson A.L., and Khairallah P.A. Effects of angiotensin II and some analogues on vascular permeability in the rabbit. Circ Res 31 (1972) 923-931
32. Tamarat R., Silvestre J.S., Durie M., and Levy B.I. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest 82 (2002) 747-756
33. Otani A., Takagi H., Suzuma K., and Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 82 (1998) 619-628
34. Richard D.E., Berra E., and Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 275 (2000) 26765-26771
35. Sahin Y., Kontas O., Muderris I, and Cankurtaran M. Effects of angiotensin converting enzyme inhibitor cilazapril and angiotensin II antagonist saralasin in ovarian hyperstimulation syndrome in the rabbit. Gynecol Endocrinol 11 (1997) 231-236
36. Gul T.G., Posaci C., and Caliskan S. The role of enalapril in the prevention of ovarian hyperstimulation syndrome: a rabbit model. Hum Reprod 16 (2001) 2253-2257
37. Pellicer A., Palumbo A., DeCherney A.H., and Naftolin F. Blockage of ovulation by an angiotensin antagonist. Science 240 (1988) 1660-1661
38. Di Carlo C., Bruno P., Cirillo D., Morgera R., Pellicano M., and Nappi C. Increased concentrations of renin, aldosterone and Ca125 in a case of spontaneous, recurrent, familial, severe ovarian hyperstimulation syndrome. Hum Reprod 12 (1997) 2115-2117
39. Morris R.S., and Paulson R.J. Increased angiotensin-converting enzyme activity in a patient with severe ovarian hyperstimulation syndrome. Fertil Steril 71 (1999) 562-563